Dear Colleagues,
As a reminder, the University Controller’s Office has created a new chart of accounts Activity value, 9105 (COVID-19) to track the financial impact of COVID-19. Please be sure to create reclassification journals for costs and/or refunded student tuition and fees directly related to COVID-19 that occurred prior to the creation of this new Activity value. In addition, this Activity value, 9105 (COVID-19), can now be used with project transactions for Non-Sponsored projects.
The recommended reports to use to monitor P&L data for this value are:
If you have questions, please contact the Financial Management Help Desk at finance_helpcenter@finance.rutgers.edu.
Regards,
Ernie DiSandro
Interim Controller
Office of the University Controller
In the spring of 2018, Peggy DeFina, CPHRM, AIC, Assistant Director of Healthcare Risk and Claims Management (HRCM), and internal stakeholders from across the university began the implementation of Med-IQ, an online learning platform that offers a library of courses customized to its clients’ curricular needs.
Just one month after Rutgers’ RUCDR Infinite Biologics received Emergency Use Authorization from the Food and Drug Administration (FDA) on April 13, 2020, for its saliva-based COVID-19 test, developed in partnership with Spectrum Solutions and Accurate Diagnostic Labs (ADL), Rutgers University–New Brunswick’s Occupational Health Department would help the university implement a strategic testing program that would govern its efforts to mitigate outbreaks among its more than 24,000 part-time and full-time faculty and staff and its population of 70,000-plus students.
